Progress in Biophysics and Molecular Biology, Journal Year: 2025, Volume and Issue: unknown
Published: April 1, 2025
Language: Английский
Biomarker Research, Journal Year: 2023, Volume and Issue: 11(1)
Published: Nov. 28, 2023
Abstract Today, adoptive cell therapy has many successes in cancer therapy, and this subject is brilliant using chimeric antigen receptor T cells. The CAR with its FDA-approved drugs, could treat several types of hematological malignancies thus be very attractive for treating solid cancer. Unfortunately, the cannot functional cancers due to unique features. This treatment method harmful adverse effects that limit their applications, so novel treatments must use new cells like NK cells, NKT macrophage Among these innate features, are more tumor seem a better candidate prior methods. have vital roles microenvironment and, direct effect, can eliminate efficiently. In addition, being part immune system, attended sites. With high infiltration, modulations effective. review investigates last achievements CAR-macrophage future immunotherapy method.
Language: Английский
Citations
45
Nature Reviews Neurology, Journal Year: 2024, Volume and Issue: 20(2), P. 84 - 98
Published: Jan. 8, 2024
Language: Английский
Citations
35
MedComm, Journal Year: 2024, Volume and Issue: 5(10)
Published: Sept. 15, 2024
The innate immune system serves as the body's first line of defense, utilizing pattern recognition receptors like Toll-like to detect pathogens and initiate rapid response mechanisms. Following this initial response, adaptive immunity provides highly specific sustained killing via B cells, T antibodies. Traditionally, it has been assumed that activates immunity; however, recent studies have revealed more complex interactions. This review a detailed dissection composition function systems, emphasizing their synergistic roles in physiological pathological contexts, providing new insights into link between these two forms immunity. Precise regulation both systems at same time is beneficial fight against immune-related diseases, for example, cGAS-STING pathway found play an important role infections cancers. In addition, paper summarizes challenges future directions field immunity, including latest single-cell sequencing technologies, CAR-T cell therapy, checkpoint inhibitors. By summarizing developments, aims enhance our understanding complexity interactions perspectives system.
Language: Английский
Citations
18
Cancers, Journal Year: 2023, Volume and Issue: 15(6), P. 1650 - 1650
Published: March 8, 2023
Historically, CD8+ T cells have been considered the most relevant effector involved in immune response against tumors and therefore focus of cancer immunotherapy approaches. However, CD4+ their secreted factors also play a crucial role tumor microenvironment can orchestrate both pro- antitumoral responses. Depending on cytokine milieu to which they are exposed, differentiate into several phenotypically different subsets with very divergent effects progression. In this review, we provide an overview current knowledge about helper system, special emphasis implication Furthermore, summarize therapeutic applications each subset its associated cytokines adoptive cell therapy cancer.
Language: Английский
Citations
30
Molecular Therapy, Journal Year: 2024, Volume and Issue: 32(7), P. 2357 - 2372
Published: May 14, 2024
Language: Английский
Citations
12
Nature Biomedical Engineering, Journal Year: 2024, Volume and Issue: unknown
Published: June 4, 2024
Language: Английский
Citations
10
Journal of The Royal Society Interface, Journal Year: 2025, Volume and Issue: 22(222)
Published: Jan. 1, 2025
This article presents the first implementation of a proportional-integral-derivative (PID) biomolecular controller within consortium different cell populations, aimed at robust regulation biological processes. By leveraging modularity and cooperative dynamics multiple engineered we develop comprehensive in silico analysis performance robustness P, PD, PI PID control architectures. Our theoretical findings, validated through experiments using BSim agent-based simulation platform for bacterial demonstrate effectiveness our multicellular strategy. innovative approach addresses critical limitations current methods, offering significant potential applications metabolic engineering, therapeutic contexts industrial biotechnology. Future work will focus on experimental validation vivo further refinement models.
Language: Английский
Citations
1
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: Feb. 26, 2025
Autologous stem cell transplantation (ASCT) and chimeric antigen receptor T-cells (CAR-T) have been used as consolidation therapies for patients with refractory/relapsed B non-Hodgkin's lymphoma (R/R B-NHL) in remission after second-line chemotherapy or salvage therapy. However, different pathological subtypes states may benefit differently from ASCT CAR-T Furthermore, treatment involving cells still poses a significant risk of disease relapse. We conducted retrospective, single-arm study 47 R/R B-NHL, found that the combination therapy improved 3-year progression-free survival (PFS) overall (OS) rates to 66.04% (95%CI: 48.311-78.928) 72.442% 53.46-84.708) respectively. has no serious adverse events. Thus, combined is effective against multiple can effectively prolong long-term patients.
Language: Английский
Citations
1
Therapeutic Advances in Hematology, Journal Year: 2025, Volume and Issue: 16
Published: Jan. 1, 2025
Acute myeloid leukemia (AML), the most common type of in adults, is a highly heterogeneous and aggressive hematologic malignancy. Since 20th century, combination cytosine arabinoside anthracyclines has been chemotherapy drug used to treat patients with AML. Although, new targeted medicines have emerged, such as midostaurin gilteritinib targeting FMS-like tyrosine kinase 3 (FLT3), ivosidenib (isocitrate dehydrogenase 1 (IDH1) inhibitor) enasidenib (IDH2 IDH, gemtuzumab ozogamicin CD33, which changed treatment strategies But, until now, hematopoietic stem cell transplantation remains best option cases. However, resistance relapse are still major consequences disease progression AML, highlighting urgent need for novel therapeutic approaches. As an alternative, chimeric antigen receptor (CAR)-T cells engineered T-cells developed breakthrough cancer therapy recent years, explored various tumor types. In particular, it achieved remarkable efficacy field relapsed refractory B lymphocyte tumors. This review mainly summarizes discusses research progress clinical application CAR-T immunotherapy AML years.
Language: Английский
Citations
1
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: Nov. 23, 2023
Cancer immunotherapies include monoclonal antibodies, cytokines, oncolytic viruses, cellular therapies, and other biological synthetic immunomodulators. These are traditionally studied for their effect on the immune system’s role in eliminating cancer cells. However, some of these therapies have unique ability to directly induce cytotoxicity cells by inducing immunogenic cell death (ICD). Unlike general stimulation, ICD triggers specific therapy-induced pathways, based release damage-associated molecular patterns (DAMPs) from dying tumour activate innate pattern recognition receptors (PRRs) subsequent adaptive responses, offering promise sustained anticancer drug efficacy durable antitumour memory. Exploring how onco-immunotherapies can trigger ICD, enhances our understanding mechanisms potential combination strategies. This review explores complexities immunotherapeutic approaches that highlighting implications system, addressing challenges treatment, emphasising pivotal contemporary research.
Language: Английский
Citations
18